An Open-Label Extension Study of LUMINENZ-AT (CM-AT)
in Children with Autism

Investigators at the University of Texas Health Science Center at Houston are conducting a 180-week clinical study to assess the long-term safety and effectiveness of an investigational medication (CM-AT/LUMINENZ- ATTM) designed to treat behavioral and gastrointestinal symptoms of autism in children.

LUMINENZ- ATTM is an enzyme formulation children take with food to help them digest proteins.  When protein is digested, it creates substances necessary for proper brain development and function.


Your child may be eligible if he/she:

 Has a diagnosis of autism,
 Is between 9 and 12 years old, and
 Has a parent who can read and sign a consent form written in English

Your child cannot participate if he/she:

 Weighs less than 48.5 pounds,
 Has allergies to pork products or pancreatic enzymes,
 Has a history of severe head trauma or stroke,
 Had a seizure within the last year, or
 Is diagnosed with chronic illnesses impacting overall health.


What is involved?

 Research participants will take the autism medication for up to 180 weeks—no pills to swallow; the tasteless medication is sprinkled on food
 Participants will receive some compensation for their time and travel

What will I receive, if eligible to participate in this research study?

 A free screening assessment

 Periodic psychological testing,

 Compensation for time and travel,

 Free study medication for up to 288 weeks, and

 Regular visits with a physician and a psychologist in our clinic.

Risks and benefits will be discussed with research participants and their parent(s) prior to enrolling in the autism study.

Where does this research study take place?

We are located in the Texas Medical Center in Houston and are part of the University of Texas Health Science Center.

Our physical address is:
The University of Texas Health Science Center at Houston
Behavioral and Biomedical Sciences Building, 2nd Floor
1941 East Rd.
Houston, TX 77054
Click here for our map

Who do I contact?

For further information and to find out if your child is eligible to participate in this autism clinical trial, please call Rosleen Mansour, Research Coordinator, at 713-486-2591 or email Rosleen.Mansour@uth.tmc.edu.

You may also complete this form and send it by:
 Email: Rosleen.Mansour@uth.tmc.edu
 Fax: 713-383-3719
 Mail: Rosleen Mansour, 1941 East Rd., Houston, TX, 77054

Printable Flyers

You may print out our flyer by clicking on the link below.


News Releases

Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism

Principal Investigator

Deborah A. Pearson, Ph.D.
Professor of Psychiatry and Behavioral Sciences
Division of Child and Adolescent Psychiatry
The University of Texas Health Science Center at Houston



Cynthia W. Santos, M.D.
Clinical Professor of Psychiatry and Behavioral Sciences
Child and Adolescent Family Clinic
The University of Texas Health Science Center at Houston

Home | News | Mission | Faculty | Staff | Labs | Current Research | Research Opportunities
Past Research | Abstracts | Clinical Services | Autism Facts | Affiliated Clinics | Helpful Links

Contact Rosleen.Mansour@uth.tmc.edu with comments or suggestions.

Privacy Policy | Open Records Policy | Legal Disclaimer | DMCA | Linking Policy | State of Texas | Statewide Search | Statutorily Required Reports
© 2003-present, Created by the Multimedia Scriptorium at The University of Texas Health Science Center at Houston

Last updated: